SK bioscience Co.,Ltd. (KRX:302440)

SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 4.23 trillion. The enterprise value is 3.88 trillion.

Market Cap	4.23T
Enterprise Value	3.88T

Important Dates

The next estimated earnings date is Thursday, January 29, 2026.

Earnings Date	Jan 29, 2026
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.37 million shares outstanding. The number of shares has increased by 2.00% in one year.

Current Share Class	78.37M
Shares Outstanding	78.37M
Shares Change (YoY)	+2.00%
Shares Change (QoQ)	-0.40%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	2.72%
Float	25.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.78
PB Ratio	2.04
P/TBV Ratio	2.48
P/FCF Ratio	n/a
P/OCF Ratio	64.22
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-657.20
EV / Sales	6.21
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-28.90

Financial Position

The company has a current ratio of 4.27, with a Debt / Equity ratio of 0.20.

Current Ratio	4.27
Quick Ratio	3.53
Debt / Equity	0.20
Debt / EBITDA	n/a
Debt / FCF	-3.06
Interest Coverage	-11.87

Financial Efficiency

Return on equity (ROE) is -0.13% and return on invested capital (ROIC) is -3.48%.

Return on Equity (ROE)	-0.13%
Return on Assets (ROA)	-3.08%
Return on Invested Capital (ROIC)	-3.48%
Return on Capital Employed (ROCE)	-4.72%
Revenue Per Employee	680.51M
Profits Per Employee	-6.43M
Employee Count	917
Asset Turnover	0.25
Inventory Turnover	3.34

Taxes

Income Tax	-83.85B
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +11.46% in the last 52 weeks. The beta is 1.15, so SK bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.15
52-Week Price Change	+11.46%
50-Day Moving Average	51,329.00
200-Day Moving Average	46,395.50
Relative Strength Index (RSI)	53.72
Average Volume (20 Days)	141,906

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 624.03 billion and -5.90 billion in losses. Loss per share was -75.30.

Revenue	624.03B
Gross Profit	75.39B
Operating Income	-122.67B
Pretax Income	-86.29B
Net Income	-5.90B
EBITDA	-35.74B
EBIT	-122.67B
Loss Per Share	-75.30

Balance Sheet

The company has 1.01 trillion in cash and 411.13 billion in debt, giving a net cash position of 595.69 billion or 7,601.08 per share.

Cash & Cash Equivalents	1.01T
Total Debt	411.13B
Net Cash	595.69B
Net Cash Per Share	7,601.08
Equity (Book Value)	2.07T
Book Value Per Share	23,447.31
Working Capital	1.05T

Cash Flow

In the last 12 months, operating cash flow was 65.90 billion and capital expenditures -200.05 billion, giving a free cash flow of -134.15 billion.

Operating Cash Flow	65.90B
Capital Expenditures	-200.05B
Free Cash Flow	-134.15B
FCF Per Share	-1,711.82

Margins

Gross margin is 12.08%, with operating and profit margins of -19.66% and -0.95%.

Gross Margin	12.08%
Operating Margin	-19.66%
Pretax Margin	-13.83%
Profit Margin	-0.95%
EBITDA Margin	-5.73%
EBIT Margin	-19.66%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.00%
Shareholder Yield	-2.00%
Earnings Yield	-0.14%
FCF Yield	-3.17%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 3.36 and a Piotroski F-Score of 3.

Altman Z-Score	3.36
Piotroski F-Score	3